Change Language

Select Language

COVID-19
The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.

Diabetic Neuropathy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2032

The Diabetic Neuropathy market is currently exhibiting strong growth. Current estimates suggest that 45%-50% of patients with diabetes will eventually develop neuropathy during their lifetimes. Driven by sedentary lifestyles, poor dietary habits, obesity, lack of physical activity, etc. we expect the number of individuals suffering from diabetes to grow robustly over the long term. This is expected to create a positive impact on the market for Diabetic Neuropathy. Furthermore, the market is also expected to be driven by several late-stage pipeline drugs with strong efficacy and safety profiles. Additionally, early diagnosis and treatment of Diabetic Neuropathy are also creating a positive impact on market growth.

Diabetic neuropathy represents a serious and common complication of diabetes. It’s a type of nerve damage that is caused by long-term high blood sugar levels. Depending on the affected nerves, diabetic neuropathy symptoms may include pain and numbness in the legs, feet, and hands. It may also result in problems with the digestive system, urinary tract, blood vessels, and heart. Some patients have mild symptoms. But for many others, however, diabetic neuropathy can be quite agonizing and painful. There are different types of diabetic neuropathy that may affect different areas of the body, causing several symptoms. Diabetic neuropathy currently doesn’t have a cure, but patients can reduce its progression. Keeping blood sugar levels within a healthy range represents the best way to reduce the likelihood of developing diabetic neuropathy and slowing its progression.

IMARC Group’s new report "Diabetic Neuropathy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2022- 2032" provides an exhaustive analysis of the Diabetic Neuropathy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The report provides an in-depth understanding of the current and future landscape of the Diabetic Neuropathy market. This includes treatment practices, in-market, and pipeline drugs, the share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool for Diabetic Neuropathy across the seven major markets. According to the report, among the seven major markets, the United States has the largest patient pool for Diabetic Neuropathy and represents the largest market for Diabetic Neuropathy treatment. Furthermore, the current Diabetic Neuropathy treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Diabetic Neuropathy market in any manner.

 

Time Period of the Study

  • Base Year: 2021
  • Historical Period: 2017-2021
  • Market Forecast: 2022-2032

 

Countries Covered

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan

 

Analysis Covered Across Each Country

  • Historical, Current, and Future Epidemiology Scenario
  • Historical, Current, and Future Performance of the Diabetic Neuropathy Market
  • Historical, Current, and Future Performance of Various Therapeutic Categories in the Diabetic Neuropathy Market
  • Sales of Various Drugs Across the Diabetic Neuropathy Market
  • Reimbursement Scenario in the Diabetic Neuropathy Market

 

Diabetic Neuropathy - In-Market and Pipeline Drugs

This report also provides a detailed analysis of the current Diabetic Neuropathy marketed drugs and late-stage pipeline drugs.

  • In-Market Diabetic Neuropathy Drugs
    • Drug Overview
    • Mechanism of Action
    • Regulatory Status
    • Clinical Trial Results
    • Drug Uptake and Market Performance
  • Late-Stage Pipeline Diabetic Neuropathy Drugs
    • Drug Overview
    • Mechanism of Action
    • Regulatory Status
    • Clinical Trial Results
    • Regulatory Status

 

Key Questions Answered in this Report

 

Market Insights

  • How has the Diabetic Neuropathy market performed so far and how will it perform in the coming years?
  • What are the markets shares of various therapeutic segments in 2021 and how are they expected to be in 2032?
  • What was the country-wise size of the Diabetic Neuropathy market across the seven major markets in 2021 and what will it look like in 2032?
  • What is the growth rate of the Diabetic Neuropathy market across the seven major markets and what will be the expected growth over the next ten years?
  • What are the key unmet needs in the Diabetic Neuropathy market?

 

Epidemiology Insights

  • What is the size of the Diabetic Neuropathy patient pool (2017-2021) across the seven major markets?
  • What would be the forecasted patient pool (2022-2032) of Diabetic Neuropathy across the seven major markets?
  • What are the key factors driving the epidemiological trend of Diabetic Neuropathy?
  • What will be the growth rate of Diabetic Neuropathy patients across the seven major markets?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies

  • What are the current marketed Diabetic Neuropathy drugs and what are their market performance?
  • What are the key pipeline Diabetic Neuropathy drugs and how are they expected to perform in the coming years?
  • How safe are the currently marketed Diabetic Neuropathy drugs and what are their efficacies?
  • How safe are the late-stage pipeline Diabetic Neuropathy drugs and what are their efficacies?
  • What are the current treatment guidelines for Diabetic Neuropathy drugs across the seven major markets?
  • Who are the key companies in the Diabetic Neuropathy market and what are their market shares?
  • What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Diabetic Neuropathy market?

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Diabetic Neuropathy - Introduction
4.1 Overview
4.2 Epidemiology (2017-2021) and Forecast (2022-2032)
4.3 Market Overview (2017-2021) and Forecast (2022-2032)
4.4 Competitive Intelligence

5 Diabetic Neuropathy - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Diabetic Neuropathy - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2017-2021)
7.2.2 Epidemiology Forecast (2022-2032)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2017-2021)
7.3.2 Epidemiology Forecast (2022-2032)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2017-2021)
7.4.2 Epidemiology Forecast (2022-2032)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2017-2021)
7.5.2 Epidemiology Forecast (2022-2032)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2017-2021)
7.6.2 Epidemiology Forecast (2022-2032)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2017-2021)
7.7.2 Epidemiology Forecast (2022-2032)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2017-2021)
7.8.2 Epidemiology Forecast (2022-2032)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2017-2021)
7.9.2 Epidemiology Forecast (2022-2032)

8 Diabetic Neuropathy - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Diabetic Neuropathy Guidelines, Management and Treatment
8.2 Diabetic Neuropathy Treatment Algorithm

9 Diabetic Neuropathy - Unmet Needs

10 Diabetic Neuropathy - Key Endpoints of Treatment

11 Diabetic Neuropathy - Marketed Products
11.1 List of Diabetic Neuropathy Marketed Drugs Across the Top 7 Markets
11.1.1    Drug Name - Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Drug and company names have not been provided here as this is a sample TOC. Complete list to be provided in the final report.

12 Diabetic Neuropathy - Pipeline Drugs
12.1 List of Diabetic Neuropathy Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name - Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Drug and company names have not been provided here as this is a sample TOC. Complete list to be provided in the final report.

13. Diabetic Neuropathy - Attribute Analysis of Key Marketed and Pipeline Drugs

14 Diabetic Neuropathy - Market Scenario
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1    Diabetic Neuropathy - Market Size
14.2.1.1 Market Size (2017-2021)
14.2.1.2 Market Forecast (2022-2032)
14.2.2    Diabetic Neuropathy - Market Size by Therapies
14.2.2.1 Market Size by Therapies (2017-2021)
14.2.2.2 Market Forecast by Therapies (2022-2032
14.3 Market Scenario - United States
14.3.1    Diabetic Neuropathy - Market Size
14.3.1.1 Market Size (2017-2021)
14.3.1.2 Market Forecast (2022-2032)
14.3.2    Diabetic Neuropathy - Market Size by Therapies
14.3.2.1 Market Size by Therapies (2017-2021)
14.3.2.2 Market Forecast by Therapies (2022-2032)
14.3.3    Diabetic Neuropathy - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1    Diabetic Neuropathy - Market Size
14.4.1.1 Market Size (2017-2021)
14.4.1.2 Market Forecast (2022-2032)
14.4.2    Diabetic Neuropathy - Market Size by Therapies
14.4.2.1 Market Size by Therapies (2017-2021)
14.4.2.2 Market Forecast by Therapies (2022-2032)
14.4.3    Diabetic Neuropathy - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1    Diabetic Neuropathy - Market Size
14.5.1.1 Market Size (2017-2021)
14.5.1.2 Market Forecast (2022-2032)
14.5.2    Diabetic Neuropathy - Market Size by Therapies
14.5.2.1 Market Size by Therapies (2017-2021)
14.5.2.2 Market Forecast by Therapies (2022-2032)
14.5.3    Diabetic Neuropathy - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1    Diabetic Neuropathy - Market Size
14.6.1.1 Market Size (2017-2021)
14.6.1.2 Market Forecast (2022-2032)
14.6.2    Diabetic Neuropathy - Market Size by Therapies
14.6.2.1 Market Size by Therapies (2017-2021)
14.6.2.2 Market Forecast by Therapies (2022-2032)
14.6.3    Diabetic Neuropathy - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1    Diabetic Neuropathy - Market Size
14.7.1.1 Market Size (2017-2021)
14.7.1.2 Market Forecast (2022-2032)
14.7.2    Diabetic Neuropathy - Market Size by Therapies
14.7.2.1 Market Size by Therapies (2017-2021)
14.7.2.2 Market Forecast by Therapies (2022-2032)
14.7.3    Diabetic Neuropathy - Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1    Diabetic Neuropathy - Market Size
14.8.1.1 Market Size (2017-2021)
14.8.1.2 Market Forecast (2022-2032)
14.8.2    Diabetic Neuropathy - Market Size by Therapies
14.8.2.1 Market Size by Therapies (2017-2021)
14.8.2.2 Market Forecast by Therapies (2022-2032)
14.8.3    Diabetic Neuropathy - Access and Reimbursement Overview
14.9   Market Scenario - Japan
14.9.1    Diabetic Neuropathy  - Market Size
14.9.1.1 Market Size (2017-2021)
14.9.1.2 Market Forecast (2022-2032)
14.9.2    Diabetic Neuropathy - Market Size by Therapies
14.9.2.1 Market Size by Therapies (2017-2021)
14.9.2.2 Market Forecast by Therapies (2022-2032)
14.9.3    Diabetic Neuropathy - Access and Reimbursement Overview

15 Diabetic Neuropathy - Recent Events and Inputs From Key Opinion Leaders

16 Diabetic Neuropathy Market - SWOT Analysis
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats     

17 Appendix


Note: We value your privacy and will never rent or sell your email address. Privacy policy

Need more help?

  •   Speak to our experienced analysts for insights on the current market scenarios.
  •   Include additional segments and countries to customize the report as per your requirement.
  •   Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  •   For further assistance, please connect with our analysts.

Purchase Options




$ 4499

REACH OUT TO US

Call us on

( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )


Drop us an email at

sales@imarcgroup.com

Social Links

4